249 related articles for article (PubMed ID: 30520145)
41. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
Erduran F; Adışen E; Aksakal AB
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
[TBL] [Abstract][Full Text] [Related]
42. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
43. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
Guo L; Feng S; Sun B; Jiang X; Liu Y
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993
[TBL] [Abstract][Full Text] [Related]
44. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
45. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
46. Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children.
Geng SL; Gong T; Ji C; Su HH
J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e1055-e1057. PubMed ID: 35876014
[No Abstract] [Full Text] [Related]
47. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
Forbes LR; Vogel TP; Cooper MA; Castro-Wagner J; Schussler E; Weinacht KG; Plant AS; Su HC; Allenspach EJ; Slatter M; Abinun M; Lilic D; Cunningham-Rundles C; Eckstein O; Olbrich P; Guillerman RP; Patel NC; Demirdag YY; Zerbe C; Freeman AF; Holland SM; Szabolcs P; Gennery A; Torgerson TR; Milner JD; Leiding JW
J Allergy Clin Immunol; 2018 Nov; 142(5):1665-1669. PubMed ID: 30092289
[TBL] [Abstract][Full Text] [Related]
48. Malignancy and Janus Kinase Inhibition.
Sivaraman P; Cohen SB
Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
[TBL] [Abstract][Full Text] [Related]
49. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.
Tavakolpour S
Dermatol Ther; 2018 Sep; 31(5):e12696. PubMed ID: 30207045
[TBL] [Abstract][Full Text] [Related]
50. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
51. Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.
Chen YL; Liu LX; Huang Q; Li XY; Hong XP; Liu DZ
Front Immunol; 2021; 12():654376. PubMed ID: 33936080
[TBL] [Abstract][Full Text] [Related]
52. Inhibiting Janus kinases to treat alopecia areata.
Divito SJ; Kupper TS
Nat Med; 2014 Sep; 20(9):989-90. PubMed ID: 25198048
[TBL] [Abstract][Full Text] [Related]
53. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia.
Chen LC; Ogbutor C; Kelley KJ; Senna MM
J Am Acad Dermatol; 2024 Jun; 90(6):1260-1262. PubMed ID: 38311243
[No Abstract] [Full Text] [Related]
54. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
King B; Lee AI; Choi J
J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
[No Abstract] [Full Text] [Related]
55. Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome.
Honda M; Moriyama M; Kondo M; Kumakura S; Murakawa Y
Scand J Rheumatol; 2020 Jul; 49(4):336-338. PubMed ID: 32329389
[No Abstract] [Full Text] [Related]
56. Tofacitinib for the treatment of moderate-to-severe psoriasis.
Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
[TBL] [Abstract][Full Text] [Related]
57. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.
Damsky W; Thakral D; Emeagwali N; Galan A; King B
N Engl J Med; 2018 Dec; 379(26):2540-2546. PubMed ID: 30586518
[TBL] [Abstract][Full Text] [Related]
58. Alopecia universalis. Partial response to tofacitinib.
Ruiz-Villaverde R; Cuenca-Barrales C; Linares-Gonzalez L; Ródenas-Herranz T
Med Clin (Barc); 2019 Aug; 153(3):e15. PubMed ID: 30718001
[No Abstract] [Full Text] [Related]
59. [Alopecia areata with good response to tofacitinib].
Maksimow A; Stintzing D; Wohlrab J
Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
[TBL] [Abstract][Full Text] [Related]
60. [Janus kinase inhibitors as a new therapeutic principle].
Heinzl S
Med Monatsschr Pharm; 2012 Oct; 35(10):350-2. PubMed ID: 23094577
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
